Tyme Technologies Inc. (TYME)

[mcsharkey]

Welcome aboard Stone. Most encouraging aspect for a quick rise is the model established by our closest competitor:[/quote]Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613® (devimistat), targets enzymes that are involved in cancer[/quote]We were attached at the hip in 2019. Then funding came through. They quickly rose to $50, now in mid-$30z.

We're both holding strong repeaentation within the Precision Promise trials being conducted by PANcreatic Cancer Action Network (PANCAN). Similar promising interim reports.

RAFAEL has a high level of Israeli backing. A little more past coverage from Israeli press ca. 2019.

As you say, it takes. Takes money too and we finally have it.

RAFAEL's CP-619 and our SM-88 seem to be THE LEADERs in the field of Cancer Metabolism Based Therapy (CMBT). Our's targets the Tyrosine amino acid which is crucial in metabolic control system.

Rafael's targets glucose consumption process later in the stages of metabolc processes.¯\_(?)_/¯

Both areas way TF over my head, but there you have it.

Pandemic has really hurt real progress in each company's trials. Hopefully, our sarcoma updates at the end of this will bring us positive news.
GKTUA